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Α)  SUMMARY 
a. Introduction  
The treatment of multiple sclerosis has witnessed major progress since the first effective 
disease modifying treatment, ß-interferon, became available in 1993. One of the most 
remarkable new treatments has been natalizumab. Proper reporting of randomized 
controlled trials for this is necessary for the assessment of their validity. 
b. Purpose  
The aim of this study was to examine the reporting quality of randomized controlled 
trials (RCTs), concerning the use of Natalizumab from patients with multiple 
sclerosis. 
c. Methods 
PubMed was searched for English-language RCTs involving patients with multiple 
sclerosis (MS). Trials were considered eligible when participants were randomly 
assigned to at least two medicinal treatment arms. Quality of reporting was assessed 
using a 39–item questionnaire based on the CONSORT checklist.  
d. Results 
Finally, 7 RCTs were deemed eligible to be included in the present study and the 
overall compliance for them was 57,8% of applicable items. 9 of the 38 items of the 
checklist were addressed in 75% or more of the studies and only 1 item reached a 
successful reporting proportion of 100%. 
e. Conclusion 
Completeness of reporting in RCTs focusing on patients with MS using Natalizumab 
still remains unsatisfactory. These results suggest that further actions should be 
taken by authors, reviewers, and editors, since inadequate reporting makes the 
interpretation of RCTs difficult if not impossible. 
 
Abbreviations and Acronyms  
RCT = randomized controlled trial  
CONSORT = Consolidated Standards of Reporting Trials  
MS = Multiple Sclerosis 
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A ΠΕΡΙΛΗΨΗ 
a. Ειςαγωγή 
Η κεραπεία τθσ ςκλιρυνςθσ κατά πλάκασ δεν είχε ιδιαίτερθ πρόοδο ζωσ τθν πρώτθ 
αποτελεςματικι κεραπεία , τθν β-ιντερφερόνθ, που δώκθκε ςε διακεςιμότθτα το 
1993. Μία από τισ αξιοςθμείωτεσ κεραπείεσ αυτισ τθσ νόςου είναι θ 
ναταλιηουμάμπθ. ΢ωςτι αναφορά τυχαιοποιθμζνων ελεγχόμενων δοκιμών γι αυτιν 
είναι απαραίτθτθ για τθν αξιολόγθςθ τθσ εγκυρότθτάσ τθσ. 
b. ΢τόχοι 
΢τόχοσ αυτισ τθσ μελζτθσ ιταν να εξετάςει τθν ποιότθτα αναφοράσ των 
τυχαιοποιθμζνων ελεγχόμενων δοκιμών που αφοροφν τθ χριςθ τθσ 
ναταλιηουμάμπθσ από αςκενείσ με ςκλιρυνςθ κατά πλάκασ. 
c. Μζθοδοι 
Πραγματοποιικθκε αναηιτθςθ ςτο PubMed για RCTs ςτθν αγγλικι γλώςςα και με 
αςκενείσ με MS. Δοκιμζσ που κρίκθκαν κατάλλθλεσ για επιλογι περιείχαν 
ςυμμετζχοντεσ που τυχαιοποιικθκαν ςε τουλάχιςτον δυο γκρουπ ιατρικισ 
κεραπείασ. Η ποιότθτα αυτισ τθσ αναφοράσ αξιολογικθκε χρθςιμοποιώντασ μια 
λίςτα 39 ερωτιςεων βαςιςμζνθ ςτθ λίςτα Consort. 
d. Αποτελζςματα 
Εν τζλει, 7 RCTs κρίκθκαν κατάλλθλα για επιλογι για να ςυμπεριλθφκοφν ςε αυτιν 
τθν ζρευνα και θ ςυνολικι ςυμμόρφωςθ τουσ με τθν Consort ιταν 57,8%. 9 ςτα 38 
ερωτιματα τθσ λίςτασ απαντικθκαν κετικά ςε ποςοςτό μεγαλφτερο του 75% και 
μόνο 1 ερώτθμα απαντικθκε κετικά κατά 100%. 
e. ΢υμπζραςμα 
Η ολοκλιρωςθ τθσ αναφοράσ των RCTs για αςκενείσ με ςκλιρυνςθ κατά πλάκασ 
που χρθςιμοποιοφν ναταλιηουμάμπθ, ακόμθ παραμζνει ανικανοποίθτθ. Αυτά τα 
αποτελζςματα προτείνουν ςε ςυγγραφείσ, κριτικοφσ και εκδότεσ να λάβουν 
περαιτζρω δράςεισ, εφόςον θ ανεπαρκισ αναφορά κακιςτά τθν ερμθνεία των RCTs 
δφςκολι, αν όχι αδφνατθ.   
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B) INTRODUCTION 
MS and Natalizumab 
Multiple sclerosis (MS) is an autoimmune condition that results in inflammatory 
damage to the central nervous system (CNS). The pathologic hallmarks of MS are 
diffuse and focal areas of inflammation, demyelination, gliosis, and neuronal injury in 
the optic nerves, brain, and spinal cord. In addition to affecting white matter tracts, 
MS results in injury to the cortical and deep gray matter. The neurologic symptoms 
and disability that patients with MS experience are a direct consequence of these 
pathologic processes, resulting in acute and chronic disruption of white matter tracts 
and gray matter structures. 
MS is the most common nontraumatic cause of neurologic disability in persons 
younger than 40 years, with an estimated prevalence of 400 000 in the United 
States. It occurs in a female–male ratio of 3 to 1. The cause of MS is multifactorial 
and is probably the cumulative result of multiple genetic and environmental risk 
factors. Twin studies have shown concordance rates between 20% and 30% in 
monozygotic twins and between 2% and 3% in dizygotic twins. Genome-wide assays 
have identified risk alleles in genes for major histocompatibility complex, interleukin-
2 receptor, and interleukin-7 receptor, among others. Geographic location of 
residence before adolescence is also predictive of MS risk, with increased rates of 
the disease in northern and southern latitudes compared with equatorial countries. 
Reduced sunlight exposure in these regions may explain some of this distribution. 
Because ultraviolet radiation to the skin is the major source of vitamin D synthesis, 
living in regions with low levels of seasonal sunlight is associated with an increased 
risk for MS in individuals with vitamin D deficiency. Risk may also be influenced by 
exposure or lack of exposure to particular infectious agents because antibodies 
against certain viruses (such as Epstein–Barr virus) are more frequently seen in 
patients with MS than in those without it. 
After more than 20 years using interferons and glatiramer acetate, an evolutionary 
improvement of patients treated with these drugs, as well as a better knowledge of 
its adverse effects and therapeutic response were observed. 
Despite the proven efficacy of the immunomodulatory drugs, some patients (from 3 
to 50%) did not respond well to treatment, showing an unsatisfactory evolution, with 
increased number of outbreaks, increased brain lesion load, and progressive 
disability. 
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Monoclonal antibodies have emerged as a therapeutic option for the treatment of 
multiple sclerosis. Natalizumabe (NTZ) is a humanized monoclonal antibody that 
binds to integrin α4B1, with a relevant immunomodulatory effect. 
 
RCTs and Consort 
The highest rank within the clinical studies is occupied by the randomized controlled 
trials (RCT) which consider to be ‘‘the most powerful tool in modern clinical 
research’’. 
Readers need to know the quality of the trials, in order to assess the strengths and 
limitations of RCTs. In addition, healthcare providers depend upon the reporting of 
methodological factors in the reports of RCTs to allow them to determine the validity 
of the trials upon which they base their clinical practice and their treatment 
guidelines. 
The evaluation of the methodological quality of a trial is connected with the quality 
of the reporting of its design, conduct and analysis. Over the years, scales and 
checklists have been developed in order to appraise the quality of RCT reports. 
 
The CONSORT (Consolidated Standards of Reporting Trials) statement is a set of 
recommendations (first published in 1996 and revised twice, in 2001 and 2010) 
aiming at helping authors improve the reporting of randomized clinical trials. It 
includes a list of necessary elements that the authors should include in their trials 
report, thus ensuring its integrity and transparency. Since its first publication, the 
CONSORT statement has been endorsed by a multitude of scientific journals and 
prominent institutions. A number of studies have examined the effect the adoption 
of the CONSORT statement has had on the quality of RCT reporting. Hopewell et al. 
compared the reporting quality for RCTs published before and after the 2001 
CONSORT revision and found it to be improved. Plint et al. compared the reporting 
quality of RCTs between journals endorsing and those not endorsing the CONSORT 
principles. For CONSORT adopters they also compared publications before and after 
their endorsement of CONSORT. They concluded that the adoption of the CONSORT 
statement had a beneficial impact on the reporting quality of RCTs. A Cochrane 
review by Turner et al. also concluded that journal adoption of the CONSORT 
statement improved the completeness of RCT reporting. Although the primary goal 
of the CONSORT statement is to guide authors to properly report RCTs, it has also 
been used as a tool for the assessment of the reporting quality of already published 
RCTs. Many studies have used the CONSORT principles in order to evaluate the 
overall reporting quality of RCTs in medical fields such as endocrinology, 
hematology, dermatology, pediatrics, otolaryngology and surgery. Few such studies 
have been conducted in the field of neurology.  
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C) METHODS 
Search plan and RCT selection 
In order to identify the randomized controlled trials to be included in the present 
study, a computerized search in Pubmed was conducted in August 2017. The search 
terms used were ‘’multiple sclerosis’’ annatalizumab’’. The filters applied were 
‘’Randomised controlled trials’’ for the article type, ‘’Humans’’ for species and 
‘’English’’ language. Search results were first screened for eligibility by title, then by 
abstract and finally by full text review when deemed necessary.  
Eligibility of Studies  
Trials were eligible if they had randomly assigned participants to at least two 
medicinal treatment arms and included patients with MS, using Natalizumab 
including all different types of the disease (Relapsing Remitting MS, Primary 
Progressive MS, Secondary Progressive MS, Clinically Isolated Syndrome and first 
demyelinating event suggestive of MS). Reports of trials on MS symptoms 
treatments, non-medicinal treatments, dose comparison studies, small pilot studies 
and any article with information resulting from a previous conducted trial (post-hoc 
analysis, sub-group analysis, sub-studies) where excluded. 
 
Data Extraction and Reporting Assessment Tool  
As assessment tool for quality of reporting of randomized controlled trials (RCTs), we used 
the CONSORT checklist, revised in 2010, which includes a 25-item checklist (Pictures 1 and 2) 
and a flow diagram (Figure 1). The checklist provides standardized approaches to report the 
trial design, analysis, and interpretation, and the diagram gives instructions to display the 
progress of all participants throughout the trial.  
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Picture 1. CONSORT 2010 checklist 
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Picture 2. CONSORT 2010 checklist (continued) 
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Figure 1. Flow diagram of the progress through the phases of a parallel randomised trial of 
two groups (enrolment, intervention allocation, follow-up, and data analysis) 
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Each item was subdivided as outlined in the CONSORT statement: 12 items were divided into 
a and b parts giving a total of 37 points scored per paper. Hence, based on CONSORT 
reporting items, we developed a 37-items data extraction sheet. We reviewed each article 
and determined whether the RCT paper reported on each of the 37 items of the revised 
CONSORT statement. 
All items were investigated in terms of whether they were reported, not whether they were 
actually carried out during the trial. Each item was characterized as ‘yes’ if it was clearly and 
adequately reported in the trial or ‘no’ if it was partially reported, unclear, or not reported at 
all. 
Each ‘yes’ answer received a score of 1 and each ‘no’ answer was scored as 0. 
We conducted a descriptive statistical analysis of all evaluated articles. Data were analyzed 
using Microsoft Excel 2007. 
In order to assess adherence to CONSORT checklist items, we calculated the number and 
proportion of trial articles that clearly and adequately reported each of the 37 CONSORT 
items (proportion of each item = the number of articles that reported the item /total 
articles-for example, if 3 of 5 RCTs reported item 8a on the checklist, that item would score 
an overall compliance score of 60%). 
Although all items in the CONSORT checklist are considered important as to improve the 
quality of reports of RCTs, emphasis was placed on reporting of methodological items which 
are more specific to assess the methodological quality of RCTs, that is sample size, 
randomization (sequence generation, allocation concealment, implementation), blinding, 
performed statistical methods, description of baseline data, precision of estimated effect 
size and reporting of ITT analysis. 
Explaining more specifically some methodological CONSORT criteria: i) randomization is the 
method used to generate the random allocation sequence, including details of any 
restriction (e.g. blocking, stratification) ii) allocation concealment is the method used to 
implement the random allocation sequence (e.g. numbered containers or central 
telephone), clarifying whether the sequence was concealed until interventions were 
assigned and iii) implementation of randomization answers the question of who generated 
the allocation sequence, who enrolled participants, and who assigned participants to their 
groups. 
The total quality of reporting score (the CONSORT score) of each trial article was calculated 
as a proportion of the ‘yes’ rated applicable items on the CONSORT checklist (possible range 
0-37 points) (CONSORT score of each article = the number of reported items/37 items-for 
example, a RCT reporting 20 of the 37 items on the checklist would score 54.1%), which was 
used to inform a global assessment of the quality of reporting. 
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D) RESULTS 
 
Search results 
The search in Pubmed yielded 39 potentially eligible articles that were screened for 
eligibility. 13 were excluded because they were not relevant or had a non medicinal 
intervention (behavioral treatment, exercise, herbal) or were not randomized trials. 
The 26 articles left reviewed by abstract and 9 excluded for the same reasons. 19 
articles searched for full text from which 10 were not found due to accessibility 
reasons. 7 articles finally were evaluated and a list of them can be found at the 
Appendix. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
PudMed identified 39 
articles 
Excluded as ineligible n= 13 
Irrelevant to topic n=9 
Other drugs n=3 
Duplication n=1 
 
Reviewed by abstract & full text 
N=26 
Excluded as ineligible n= 19 
Irrelevant to topic n=8 
Other language n=1 
No accessibility n=10 
Articles included in the analysis 
N=7 
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Eligible trials 
Finally, 7 RCTs were deemed eligible to be included in the present study. A full list of 
these RCTs is provided in the Appendix. Table 1 shows some basic characteristics of 
the included trials. 
Table 1. 
Characteristic Categories Number of RCTs 
 
 
 
Journal of  
Publication 
The new England journal 2 
Neurology 1 
Original communication 1 
Elsevier 2 
Journal of neuro-
opthalmogy 
1 
 
Number of authors 
≤ 10 5 
>10 2 
 
 
Year of publication 
2003 1 
2006 1 
2013 1 
2014 2 
2015 1 
2017 1 
 
Type of control 
Placebo 6 
Active control 3 
 
Funding source 
Pharmaceutical 
industries 
6 
Others 1 
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Blinding 
Blinded 5 
Open-label 2 
 
RCT arms 
2 5 
>2 2 
 
 
 
Reporting quality results 
The overall compliance for the 7 RCTs was 57,8% of applicable items.  
Compliance figures for each item are summarized in Table 2. 
CONSORT items have been variedly reported in the 69 RCTs. Compliance for each 
item ranges widely from 14% of trials to even 100% of trials (where the item is 
applicable). Items best reported (in >75% of RCTs) are: 
 Item 1b (from the ‘’title and abstract’’ section), concerning the Structured 
summary of trial design, methods, results and conclusions, reported in 6 out 
of 7 RCTs 
 Item 2a (from the ‘’background and objectives’’ section), concerning the 
Scientific background and explanation of rationale, reported in 6 out of 7 
RCTs. 
 Item 4a (from the ‘’participation’’ section) regarding to the eligibility criteria 
for participants, reported in 6 out of 7 RCTs. 
 Item 5 (from the ‘’interventions’’ section) regarding to the interventions for 
each group with sufficient details to allow replication, including how and 
when they were actually administered, reported in 6 out of 7 RCTs. 
 Item 12a (from the ‘’statistical methods’’ section) according to Statistical 
methods used to compare groups for primary and secondary outcomes, 
reported in 6 out of 7 RCTs. 
 Item 13b (from the ‘’participant flow’’ section) concerning the losses and 
exclusions after randomization, together with reasons, for every group, 
reported in 6 out of 7 RCTs. 
 Item 16 (from the ‘’number analyzed’’ section) regarding to the number of 
participants (denominator) included in each analysis and whether the 
analysis was by original assigned groups, reported in 6 out of 7 RCTs. 
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 Item 17a (from the ‘’outcomes and estimation’’ section) concerning the 
results for each group, and the estimated effect size and its precision (such as 
95% confidence interval) for each primary and secondary outcomes, reported 
in 6 out of 7 RCTs. 
 
It should be noted that only item 13a concerning the numbers of participants who 
were randomly assigned, received intended treatment, and were analyzed for 
primary outcome, for every group, respectively, reached a successful reporting 
proportion of 100% of the trials where it was applicable. 
 
Table 2. Absolute number and proportion of RCTs reporting each of the CONSORT 
items 
Data item Number of RCTs 
reported 
Proportion 
 
1a  4 0.57 
1b  6 0.85 
2a Background and objectives 6 0.85 
2b 2 0.28 
3a Trial design 5 0.71 
3b 3 0.42 
4a Participations 6 0.85 
4b 4 0.57 
5 Interventions 6 0.85 
6a Outcomes 
 
5 0.71 
6b 2 0.28 
7a Sample size 2 0.28 
7b 2 0.28 
8a Sequence generation 
 
5 0.71 
8b 4 0.57 
9 Allocation concealment 
Mechanism 
1 0.14 
10 Implementation 2 0.28 
11a Blinding 
 
2 0.28 
11b 2 0.28 
12a Statistical methods 6 0.85 
12b 5 0.71 
13a Participant flow (a diagram is 
strongly recommended) 
7 1 
13b 6 0.85 
14a Recruitment 
 
2 0.28 
14b 3 0.42 
15 Baseline data 5 0.71 
16 Number analyzed 6 0.85 
17a Outcomes and estimation 6 0.85 
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17b 3 0.42 
18 Ancillary analyses 3 0.42 
19 Harms 4 0.57 
20 Limitation 3 0.42 
21 Generalizability 2 0.28 
22 Interpretation 5 0.71 
23 Registration 4 0.57 
24 Protocol 4 0.57 
25 Funding 4 0.57 
 
 
On the contrary, successful reporting was particularly low (<25% of RCTs) for the 
item 9 regarding to the mechanism used to implement the random allocation 
sequence (such as sequentially numbered containers), describing any steps taken to 
conceal the sequence until interventions were assigned. That item is reported in the 
14% of the articles although it’s an important methodological technique which 
should always be reported. 
  
E) CONCLUSION 
This thesis has evaluated the reporting quality of randomized controlled trials in the 
therapy of multiple sclerosis with natalizumab. The reports of 7 eligible trials were 
reviewed using the CONSORT 2010 statement as an assessment tool. 
CONSORT, came about because of the need to provide readers with enough valid 
and meaningful information concerning the design, conduct, and analysis of RCTs, 
therefore it is expected that the CONSORT statement will ultimately lead to more 
comprehensive and complete reporting of RCTs. However our results summarized 
indicate that reports of RCTs involving patients with Multiple Sclerosis do not as yet 
conform to the CONSORT recommendations, neither have we found strong 
indications of improvement over time. 
Many of the CONSORT checklist items are only reported in a minority of RCTs. Rather 
alarming is the fact that crucial methodological aspects for a RCT are underreported. 
Details about randomization, blinding, trial setup and timeframe are most often 
omitted. Information concerning harms, funding sources and protocol access are 
also frequently withheld. Summaries are also far from being written in a manner that 
best provides the reader with all the necessary information. 
Nevertheless, some CONSORT items seem to be adequately reported in most of the 
trials: those referring to the scientific background, nature of interventions, eligibility 
criteria, statistical methods, baseline patient characteristics, interpretation of results. 
Institutional Repository - Library & Information Centre - University of Thessaly
07/06/2020 02:58:54 EEST - 137.108.70.13
  ΚΟΜΑΣ΢ΙΟΤΛΗ ΒΑ΢ΙΛΙΚΗ 
15 
 
However, these better reported items seem to represent more theoretical aspects of 
the trial. 
This study has some limitations. First of all, the assessment of each report’s 
compliance to the CONSORT items was undertaken by a single person, the author, 
thus rendering the procedure prone to subjectivity. The evaluation of each item was 
a rather complex procedure since no exact criteria exist as to what constitutes a 
positive or negative response. In order to address this problem, the CONSORT2010 
Explanation and Elaborations document was thoroughly studied and each item was 
broken down into component elements derived from the document’s elaboration on 
it. A positive response was accepted only when all of the component elements were 
met. Partial and ambiguous responses were counted as negative. 
According to the above, the present study concluded that the reporting quality of 
the included RCTs for multiple sclerosis was suboptimal, even for key aspects of trial 
methodology. Due to the need for more effective treatments for multiple scleprosis, 
randomized controlled clinical trials will once again serve as the optimum way of 
verifying the safety and efficacy of new therapies. Better reports in terms of 
completeness and transparency, will help the scientific community evaluate their 
validity and reach safe decisions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Institutional Repository - Library & Information Centre - University of Thessaly
07/06/2020 02:58:54 EEST - 137.108.70.13
  ΚΟΜΑΣ΢ΙΟΤΛΗ ΒΑ΢ΙΛΙΚΗ 
16 
 
REFERENCES 
1. Pfeifer MP, Snodgrass GL. The continued use of retracted, invalid scientific 
literature. Jama. 1990;263(10):1420-3. 
2. Turner L, Shamseer L, Altman DG, Weeks L, Peters J, Kober T, et al. 
Consolidated standards of reporting trials (CONSORT) and the completeness 
of reporting of randomised controlled trials (RCTs) published in medical 
journals. The Cochrane database of systematic reviews. 2012;11:Mr000030. 
3. CONSORT 2010 statement: extension to randomised pilot and feasibility trials 
Sandra M. Eldridge, Claire L. Chan, Michael J. Campbell, Christine M. Bond, 
Sally Hopewell, Lehana Thabane, Gillian A. Lancaster, on behalf of the PAFS 
consensus group 
4. The CONSORT statement: revised recommendations for improving the quality 
of reports of parallel group randomized trials David Moher, Kenneth F Schulz, 
Douglas G Altman BMC Med Res Methodol. 2001; 1: 2. Published online 2001 
Apr 20. doi: 10.1186/1471-2288-1-2 
5. Does use of the CONSORT Statement impact the completeness of reporting 
of randomised controlled trials published in medical journals? A Cochrane 
reviewa Lucy Turner, Larissa Shamseer, Douglas G Altman, Kenneth F Schulz, 
David Moher Syst Rev. 2012; 1: 60. Published online 2012 Nov 29. doi: 
10.1186/2046-4053-1-60 PMCID: PMC3564748 
6. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of 
randomized controlled trials: the CONSORT statement. JAMA. 1996;276:673-
639.  
7. Mosteller F, Gilbert JP, McPeek B: Reporting standards and research 
strategies for controlled trials: Agenda for the editor. Controlled Clin Trials 
1:37-58, 1980  
8. Pfeifer, M.P., Snodgrass,G.L., 1990. The continued use of retracted, invalid 
scientific literature. J. Am. Med. Assoc. 263,1420–1423. 
9. Treatment of progressive multiple sclerosis: what works, what does not, and 
what is needed Prof Anthony Feinstein, MD'Correspondence information 
about the author Prof Anthony FeinsteinEmail the author Prof Anthony 
Feinstein, Jenny Freeman, PhD, Albert C Lo, MD Published: February 2015 
Treatment of progressive multiple sclerosis: what works, what does not, and 
what is needed DOI: http://dx.doi.org/10.1016/S1474-4422(14)70231-5 
10. Print version ISSN 0004-282X Arq. Neuro-Psiquiatr. vol.71 no.3 São Paulo 
Mar. 2013  http://dx.doi.org/10.1590/S0004-282X2013000300001 EDITORIAL 
Natalizumab and multiple sclerosis PhD, Neurologista, Chefe de Clínica das 
Enfermarias de Neurologia da, Santa Casa de Misericórdia do Rio de Janeiro 
2Responsável pelo Ambulatório de Doenças Desmielinizantes da, Santa Casa 
da Misericórdia do Rio de Janeiro, Rio de Janeiro, RJ, Brazil 
Institutional Repository - Library & Information Centre - University of Thessaly
07/06/2020 02:58:54 EEST - 137.108.70.13
  ΚΟΜΑΣ΢ΙΟΤΛΗ ΒΑ΢ΙΛΙΚΗ 
17 
 
11. Eur J Neurol. 2015 Mar;22(3):570-7. doi: 10.1111/ene.12618. Epub 2014 Dec 15. 
Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results 
from the prospective TIMER study and a retrospective analysis of AFFIRM. 
Voloshyna N1, Havrdová E, Hutchinson M, Nehrych T, You X, Belachew S, Hotermans 
C, Paes D. 
12. BMC Neurol. 2014 Feb 12;14:27. doi: 10.1186/1471-2377-14-27. Natalizumab 
treatment for multiple sclerosis: Middle East and North Africa regional 
recommendations for patient selection and monitoring. Alroughani RA1, Aref HM, 
Bohlega SA, Dahdaleh MP, Feki I, Al Jumah MA, Al-Kawi MZ, Koussa SF, Sahraian MA, 
Alsharoqi IA, Yamout BI. 
13. Lai TY, Wong VW, Lam RF, Cheng AC, Lam DS, Leung GM. Quality of reporting of key 
methodological items of randomized controlled trials in clinical ophthalmic journals. 
Ophthalmic epidemiology. 2007;14(6):390-8. 
14. Signori A, Baccino A, Sormani MP. The quality of reports of randomized trials 
in multiple sclerosis: a review. Multiple sclerosis (Houndmills, Basingstoke, 
England). 2012;18(6):776-81. 
15. Berer K, Krishnamoorthy G. Microbial view of central nervous system 
autoimmunity. FEBS letters. 2014;588(22):4207-13. 
16. PJ, Choi PT, El-Dika S, Bhandari M, Montori VM, Schünemann HJ,...& Guyatt 
GH, 2004. An observational study found that authors of randomized  
ontrolled trials frequently use concealment of randomization and blinding, 
despite the failure to report these methods. J Clin Epidemiol 57:1232–1236. 
17.  Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M,…&Klassen TP, 
1998. Does quality of reports of randomised trials affect estimates of 
intervention efficacy reported in meta-analyses? Lancet. 352(9128):609-13. 
 
 
 
 
 
 
 
 
 
 
 
Institutional Repository - Library & Information Centre - University of Thessaly
07/06/2020 02:58:54 EEST - 137.108.70.13
  ΚΟΜΑΣ΢ΙΟΤΛΗ ΒΑ΢ΙΛΙΚΗ 
18 
 
APPENDIX 
 
List of articles included in the study 
1. MS disease activity in RESTORE, A randomized 24-week natalizumab treatment 
interruption study. Robert J. Fox, MD Bruce A.C. Cree, MD, PhD, MCR  Jerome De 
Sèze, MD Ralf Gold, MD Hans-Peter Hartung, MD Douglas Jeffery, MD, PhD Ludwig 
Kappos, MD Michael Kaufman, MD Xavier Montalbán, MD, PhD Bianca Weinstock- 
Guttman, MD Britt Anderson, PhD Amy Natarajan, MS Barry Ticho, MD, PhD Petra 
Duda, MD, PhD 
2. The new England journal of medicine, established in 1812 march 2, 2006 vol. 354 no. 
9 A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple 
Sclerosis Chris H. Polman, M.D., Paul W. O’Connor, M.D., Eva Havrdova, M.D., 
Michael Hutchinson, M.D., Ludwig Kappos, M.D., David H. Miller, M.D., J. Theodore 
Phillips, M.D., Ph.D., Fred D. Lublin, M.D., Gavin Giovannoni, M.D., Andrzej Wajgt, 
M.D., Martin Toal, M.B., M.F.P.M., Frances Lynn, M.Sc., Michael A. Panzara, M.D., 
M.P.H., and Alfred W. Sandrock, M.D., Ph.D., for the AFFIRM Investigators* 
3. Natalizumabreducesrelapseclinicalseverity and improves relapse recovery in MS$ 
Fred D.Lublina,n, GaryCutterb, GavinGiovannonic, AmyPaced, Nolan RCampbelld, 
ShibeshihBelachewd aIcahn  
4. Clinical effects of natalizumab on multiple sclerosis appear early in treatment course 
Ludwig Kappos • Paul W. O’Connor • Christopher H. Polman • Patrick Vermersch • 
Heinz Wiendl • Amy Pace • Annie Zhang • Christophe Hotermans 
5. A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis, David H. Miller, 
M.D., Omar A. Khan, M.D., William A. Sheremata, M.D., Lance D. Blumhardt, M.D., 
George P.A. Rice, M.D., Michele A. Libonati, M.S., Allison J. Willmer-Hulme, Ph.D., 
Catherine M. Dalton, M.B., Katherine A. Miszkiel, M.B., and Paul W. O’Connor, M.D., 
for the International Natalizumab Multiple Sclerosis Trial Group* 
6. Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis 
patients: A double-blind, randomized controlled trial and openlabel pharmacokinetic 
study Takahiko Saidaa,⁎, Jun-ichi Kirab, Shuji Kishidac, Takashi Yamamurad, Yukiko 
Sudoe, Kazutaka Ogiwarae, JT Tibunge, Nisha Lucasf, Meena Subramanyamf, On 
behalf of Natalizumab Trial Principal Investigators 
7. Vision in a Phase 3 Trial of Natalizumab for Multiple Sclerosis: Relation to Disability 
and Quality of Life Salim Chahin, MD,corresponding author Laura J. Balcer, MD, 
MSCE, Deborah M. Miller, PHD, Annie Zhang, MD, MPH, and Steven L. Galetta, MD, 
FAAN 
Institutional Repository - Library & Information Centre - University of Thessaly
07/06/2020 02:58:54 EEST - 137.108.70.13
